The US Food and Drug Administration (FDA) has approved a novel antibiotic, daptomycin, for parenteral treatment of major abscesses and other skin and skin-structure infections. The approval “is very ...

The analysis revealed that daptomycin resistance in VRE is caused by an amino-acid substitution (rpoB) within the bacterial RNA of VRE that's associated with the use of rifaximin, an antibiotic ...

aureus, have been recently developed. Novel antibiotics, such as linezolid, daptomycin and tigecycline, have been successfully introduced into clinics. Several other antibiotics of different ...

This is an area of true need....There has not been a new antibiotic approved for the treatment of S. aureus bacteremia for over 15 years. Among the secondary outcomes, mortality was 9.0% and in the ...

Background Daptomycin is a concentration dependent antibiotic with particular sensitivity to strains of Staphylococcus aureus. Its novel mechanism of disrupting cell membranes makes it particularly ...

The purpose of this meta-analysis was to compare the safety and efficacy of daptomycin with other antibiotics, especially with vancomycin which has long been considered the standard therapy for ...